View More Recent Stories
-
Clearmind Medicine (CMND) Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
-
SciSparc (SPRC) Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
-
SciSparc (SPRC): MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
-
SciSparc (SPRC) Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
-
SciSparc (SPRC) Issues Update Regarding the Status of the AutoMax Merger
-
SciSparc (SPRC) and Clearmind Medicine (CNMD) Announce New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
-
SciSparc (SPRC) Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
-
SciSparc (SPRC) Announces Receipt of Nasdaq Minimum Bid Price Notification
-
SciSparc (SPRC) Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
-
SciSparc (SPRC) Enters Non-binding LoI for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio
